A Phase 2 interventional study of Rotigotine in Restless Legs Syndrome, sponsored by UCB Pharma. Completed at 24 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 4th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 2, and was the 6th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
This study's enrollment of 295 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
17 studies in Restless Legs Syndrome by UCB S.A.: none open now, none under way, none of them phase 3. Of 17 finished, 11 (65%) have results posted.
Among the 17 studies in Restless Legs Syndrome by UCB S.A., this one is the 5th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2003, is one of 5 in phase 2, and was the 7th registered.
UCB S.A.’s Restless Legs Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 17 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label extension trial conducted at the same European sites that participated in trial SP 709 (NCT00243217). The trial is designed to collect long-term safety and tolerability, efficacy correlates, and quality of life data in subjects with idiopathic Restless Leg Syndrome (RLS). The duration of treatment is approximately 5 years. Subject will be up-titrated to their optimal dose (administration of 1 patch per day, 5 different doses and patch sizes).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rotigotine trans-dermal patch
Drug: Rotigotine
Rotigotine transdermal patches once daily: 2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)
Also known as: Neupro®
Number of Subjects With at Least One Adverse Event, as Reported Spontaneously by the Subject or Observed by the Investigator, During the 5-year Open-label Extension.
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: Up to five years
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event During the 5-year Open Label Extension
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: Up to five years
A total of 295 subjects belong to the Enrolled Set (ES) and all of them received at least one dose of trial medication, so they all belong to the Safety Set (SS).
| Milestone | Rotigotine |
|---|---|
| Started | 295 |
| Completed | 122 |
| Not completed | 173 |
| Withdrew: Protocol violation | 10 |
| Withdrew: Lack of efficacy | 31 |
| Withdrew: Adverse event | 89 |
| Withdrew: Unsatisfactory compliance of subject | 12 |
| Withdrew: Withdrawal by subject | 18 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Other | 10 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| participants | Rotigotine |
|---|---|
| Number of Subjects With at Least One Adverse Event, as Reported Spontaneously by the Subject or Observed by the Investigator, During the 5-year Open-label Extension. | 273 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| participants | Rotigotine |
|---|---|
| Number of Subjects Who Withdrew From the Trial Due to an Adverse Event During the 5-year Open Label Extension | 93 |
Collected over Adverse Events (AEs) were collected over the whole trial period up to 5 years from Visit 1 to the Safety Follow- up Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 79/295 (26.8%) | 272/295 (92.2%) |
| Event | Rotigotine |
|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 11/295 |
| Myocardial infarctionCardiac disorders | 4/295 |
| Toe deformityMusculoskeletal and connective tissue disorders | 4/295 |
| Radius fractureInjury, poisoning and procedural complications | 3/295 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/295 |
| SyncopeNervous system disorders | 3/295 |
| Varicose veinVascular disorders | 3/295 |
| Coronary artery diseaseCardiac disorders | 2/295 |
| GoitreEndocrine disorders | 2/295 |
| NauseaGastrointestinal disorders | 2/295 |
| Event | Rotigotine |
|---|---|
| Application site erythemaGeneral disorders | 96/295 |
| Application site reactionGeneral disorders | 74/295 |
| NasopharyngitisInfections and infestations | 55/295 |
| Application site pruritusGeneral disorders | 54/295 |
| Back painMusculoskeletal and connective tissue disorders | 40/295 |
| NauseaGastrointestinal disorders | 35/295 |
| FatigueGeneral disorders | 31/295 |
| HypertensionVascular disorders | 26/295 |
| DepressionPsychiatric disorders | 22/295 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/295 |
| Age, Categorical(Participants) | Rotigotine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 208 |
| >=65 years | 87 |
| Age, Continuous(years) | Rotigotine |
|---|---|
| Mean | 58.3 ± 10.1 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 196 |
| Male | 99 |
| Body Mass Index (BMI)(kg/ m^2) | Rotigotine |
|---|---|
| Mean | 26.37 ± 3.84 |
| Height(cm) | Rotigotine |
|---|---|
| Mean | 167.5 ± 8.3 |
| Weight(kilogram (kg)) | Rotigotine |
|---|---|
| Mean | 74.21 ± 13.19 |
The record gives a start of Jul 2003, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine